logo

Unum Therapeutics Inc. (UMRX)



Trade UMRX now with
  Date
  Headline
9/18/2018 6:49:15 AM Wedbush Reiterates Unum Therapeutics Inc. (UMRX) At Outperform With $20 Price Target
9/17/2018 7:08:13 AM Unum Therapeutics To Present Data On Dose Level 1 Of The ATTCK-20-03 Phase I Study Of ACTR707 With Rituximab
8/14/2018 6:41:49 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) Q4 18 Rev. Estimate To 2.9 M From 2.4 M
8/14/2018 6:41:40 AM Wedbush Is Increasing Unum Therapeutics Inc. (UMRX) Q3 18 Rev. Estimate To 2.9 M From 2.4 M
8/14/2018 6:41:08 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) FY18 Estimate To -1.72 From -1.80
8/14/2018 6:40:51 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) Q4 18 Estimate To -0.39 From -0.41
8/14/2018 6:40:36 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) Q3 18 Estimate To -0.36 From -0.38
8/14/2018 6:40:12 AM Wedbush Reiterates Unum Therapeutics Inc. (UMRX) At Outperform With $20 Up From $18 Price Target
8/13/2018 4:13:11 PM Unum Therapeutics Q2 Loss/share $0.31 Vs. Loss $0.58 Year Ago
7/12/2018 7:09:00 AM Unum Therapeutics To Present Pre-Clinical Data On Antibody-Coupled T Cell Receptor Platform At ASH Summit
5/15/2018 7:48:23 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) FY19 Estimate To -1.45 From -1.46
5/15/2018 7:48:09 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) Q3 19 Estimate To -0.38 From -0.39
5/15/2018 7:47:47 AM Wedbush Is Lowering Unum Therapeutics Inc. (UMRX) FY18 Estimate To -1.80 From -1.47
5/15/2018 7:47:13 AM Wedbush Reiterates Unum Therapeutics Inc. (UMRX) At Outperform With $18 Price Target
5/14/2018 7:07:36 AM Unum Therapeutics Q1 Net Loss Attributable $6.8 Mln Or $0.66/Shr Vs Loss $5.96 Mln Or $0.58/Shr Last Year
4/23/2018 8:34:34 AM Wedbush Initiates Unum Therapeutics Inc. (UMRX) At Outperform With $18 Price Target